

24-1820 & 24-1821

IN THE

United States Court of Appeals

FOR THE THIRD CIRCUIT

Bristol Myers Squibb, *et al.*,

Plaintiff- Appellants,

---v.---

Xavier Becerra, *et al.*,

Defendant- Appellees.

Janssen Pharmaceuticals, *et al.*,

Plaintiffs- Appellants,

---v. ---

Xavier Becerra, *et al.*,

Defendant- Appellees.

ON APPEAL FROM THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY, Nos. 3:23-cv-03335 & 3:23-cv-03818

**BRIEF OF LAW SCHOLARS AS *AMICUS CURIAE* IN SUPPORT
OF APPELLEES AND AFFIRMANCE**

Hannah W. Brennan

Claudia Morera

Rebekah Glickman-Simon

Hagens Berman Sobol Shapiro LLP

One Faneuil Hall Sq., 5th Floor

Boston, MA 02109

Telephone: (617) 482-3700

Facsimile: (617) 482-3003

hannahb@hbsslaw.com

claudiam@hbsslaw.com

rebekahgs@hbsslaw.com

Counsel for Proposed Amicus

Curiae Law Scholars

TABLE OF CONTENTS

IDENTITY AND INTERESTS OF PROPOSED AMICUS CURIAE	9
I. INTRODUCTION	9
II. PROCEDURAL HISTORY	14
III. ARGUMENT	15
A. The government can, and routinely does, negotiate to form contracts for goods and services, including drugs, without implicating the Takings Clause.....	15
B. Congress has the authority to regulate drug prices directly, and even a price regulation applied to the whole pharmaceutical industry would be constitutional.....	20
C. A ruling that the Medicare drug price negotiations constitute a per se taking would upend the Medicare, Medicaid, and Veterans Administration programs. 32	
IV. CONCLUSION	34
V. SIGNATORIES.....	34
CERTIFICATE OF COMPLIANCE	42
CERTIFICATE OF SERVICE.....	43

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>74 Pinehurst LLC v. New York</i> , 59 F.4th 557 (2d Cir. 2023)	28
<i>Aetna Ins. Co. v. Hyde</i> , 275 U.S. 440 (1928).....	29
<i>Associated Builders & Contractors Inc. v. City of Jersey City</i> , 836 F.3d 412 (3d Cir. 2016)	15
<i>AstraZeneca Pharms. LP v. Becerra</i> , No. 23-cv-00931, 2024 WL 895036 (D. Del. Mar. 1, 2024).....	12
<i>Baker Cnty. Med. Servs., Inc. v. U.S. Atty. Gen.</i> , 763 F. 3d 1274 (11th Cir. 2014)	34
<i>Boehringer Ingelheim Pharms., Inc. v. HHS</i> , No. 3:23-cv-1103, 2024 WL 3292657 (D. Conn. July 3, 2024).....	12
<i>Bristol Myers Squibb Co. v. Becerra</i> , Civ. A. No. 23-3335, ECF No. 1 (D.N.J. June 16, 2023).....	21
<i>Burditt v. U.S. Dep’t of Health & Hum. Servs</i> , 934 F. 2d 1362 (5th Cir. 1991)	34
<i>Coyne-Delany Co. v. Cap. Dev. Bd.</i> , 616 F.2d 341 (7th Cir. 1980)	15
<i>Curtiss-Wright Corp. v. McLucas</i> , 364 F. Supp. 750 (D.N.J. 1973).....	16
<i>Dayton Area Chamber of Com. v. Becerra</i> , No. 2:23 CV 156, 2024 WL 3741510 (S.D. Ohio Aug. 8, 2024).....	12
<i>Duquesne Light Co. v. Barasch</i> , 488 U.S. 299 (1989).....	30, 31
<i>Eli Lilly & Co. v. United States Dep’t of Health & Human Servs.</i> , No. 21-cv-00081, 2021 WL 5039566 (S.D. Ind. Oct. 29, 2021).....	18, 19

<i>Energy Reserves Group, Inc. v. Kansas Power and Light Co.</i> , 459 U.S. 400 (1983).....	28
<i>Exxon Corp. v. Eagerton</i> , 462 U.S. 176 (1983).....	20
<i>Fed. Power Comm’n v. Hope Nat. Gas Co.</i> , 320 U.S. 591 (1944).....	30, 31
<i>Fed. Power Comm’n v. Sierra Pac. Power Co.</i> , 350 U.S. 348 (1956).....	31
<i>Hegeman Farms v. Baldwin</i> , 293 U.S. 163 at 170 (1934).....	29
<i>Honolulu Rapid Transit Co. v. Dolim</i> , 459 F.2d 551 (9th Cir. 1972)	16
<i>Horne v. Dep’t of Agric.</i> , 576 U.S. 350 (2015).....	21, 22, 23, 24
<i>Hughes Commc’ns Galaxy, Inc. v. United States</i> , 271 F.3d 1060 (Fed. Cir. 2001)	16, 19
<i>J.H. Rutter Rex Mfg. Co. v. United States</i> , 706 F.2d 702 (5th Cir. 1983)	15
<i>Klump v. United States</i> , 50 Fed. Cl. 268 (2001), <i>aff’d</i> , 30 F. App’x 958 (Fed. Cir. 2002).....	16
<i>Leonard v. Earle</i> , 141 A. 714 (1928), <i>aff’d</i> , 279 U.S. 392 (1929).....	21
<i>Perkins v. Lukens Steel Co.</i> , 310 U.S. 113 (1940).....	15, 16
<i>Permian Basin Area Rate Cases</i> , 390 U.S. 747, 769 (1968).....	31
<i>Pittsburgh & Lake Erie R.R. Co. v. Ry. Labor Execs’ Ass’n</i> , 491 U.S. 490 (1989).....	30
<i>Price Administr. Bowles v. Willingham</i> , 321 U.S. 503, 517 (1944).....	30

<i>Ruckelshaus v. Monsanto Co.</i> , 467 U.S. 986 (1984).....	22, 23, 24
<i>Sanofi-Aventis U.S., LLC v. U.S. Dep’t of Health & Hum. Servs.</i> , 570 F. Supp. 3d 129, 209-10 (D.N.J. 2021), <i>aff’d in part, rev’d in part sub nom. Sanofi Aventis U.S. LLC v. United States Dep’t of Health & Hum. Servs.</i> , 58 F.4th 696 (3d Cir. 2023), <i>judgment entered</i> , No. 21-3167, 2023 WL 1325507 (3d Cir. Jan. 30, 2023).....	18, 19
<i>St. Christopher Assocs., L.P. v. United States</i> , 511 F.3d 1376 (Fed. Cir. 2008)	16
<i>United States v. White</i> , 765 F.2d 1469 (11th Cir. 1985)	17
<i>Yee v. City of Escondido, Cal.</i> , 503 U.S. 519 (1992).....	29, 30

Statutes

42 C.F.R. § 423.120 (2024)	26
48 C.F.R. § 15.405 (2022)	16
38 U.S.C. § 8126.....	17
38 U.S.C. § 8126(a)	26
38 U.S.C. § 8126(a)(2).....	17
38 U.S.C. § 8126(a)(4).....	18
42 U.S.C. §§ 256b.....	17
42 U.S.C. § 256b(1)	26
42 U.S.C. § 256b(a)(1), (10).....	17
42 U.S.C. § 1395cc(a)(1)(I)(i)	34
42 U.S.C. § 1395dd.....	34
42 U.S.C. § 1395w-3b.....	26

42 U.S.C. § 1395w-101(a)(1)	26, 27
42 U.S.C. §§ 1395w-102, 104(b)(3)	26
42 U.S.C. § 1395w-111 (2018).....	28
42 U.S.C. § 1396d(12)	26
42 U.S.C. §§ 1396r-8(a).....	17
42 U.S.C. §§ 1396r-8(a)(1), (a)(5)(A)	18
42 U.S.C. § 1396r-8(d)(1).....	26
P.L. 117-169, § 11101.....	19
U.S. Const. Art. I § 8, Cl. 8.....	22
Other Authorities	
<i>A Snapshot: Government-Wide Contracting</i> , GOVERNMENT ACCOUNTABILITY OFFICE (May 2023), https://gaoinnovations.gov/Federal_Government_Contracting	17
Aaron S. Kesselheim, Jerry Avorn & Amet Sarpatwari, <i>The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform</i> , 316 (8) JAMA 858 (2016).....	10, 28
Aaron S. Kesselheim, Michael S. Sinha & Jerry Avorn, <i>Determinants of Market Exclusivity for Prescription Drugs in the United States</i> , 177 (11) JAMA INTERNAL MED. 1 (2017).....	10
Amy Kapczynski, Chan Park & Bhavan Sampat, <i>Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents</i> , 7 PLOS ONE 1, 6-7 (2012)	25
Ashley Kirzinger et al., <i>Public Opinion on Prescription Drugs and Their Prices</i> , THE KAISER FAMILY FOUNDATION (Aug. 21, 2023), https://www.kff.org/health-costs/poll-finding/public-opinion-on- prescription-drugs-and-their-prices/	9
<i>Baseline Projections: Medicare</i> , CONG. BUDGET OFF. (May 2023).....	27

David Austin & Tamara Hayford, <i>Prescription Drugs: Spending, Use, and Prices</i> 8, CONG. BUDGET OFF. (Jan. 2022).	27
David Austin & Tamara Hayford, <i>Research & Development in the Pharmaceutical Industry</i> 18-20, CONG. BUDGET OFF. (2021).....	24
Deena Beasley, <i>U.S. Will Still Pay at Least Twice as Much After Negotiating Drug Prices</i> , Reuters (Sept. 3, 2024).....	11
<i>Drug Industry and HMOs Deployed an Army of Nearly 1,000 Lobbyists to Push Medicare Bill, Report Finds</i> , PUB. CITIZEN (June 23, 2004), https://www.citizen.org/news/drug-industry-and-hmos-deployed-an-army-of-nearly-1000-lobbyists-to-push-medicare-bill-report-finds	11
Ekaterina Galkina Cleary, Matthew J. Jackson, Edward W. Zhou & Fred D. Ledley, <i>Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019</i> , 4 JAMA HEALTH F. 1, 1 (2023)	24
Elizabeth Williams et al., <i>Medicaid Financing: The Basics</i> , KAISER FAMILY FOUNDATION (Apr. 13, 2023), https://www.kff.org/medicaid/issue-brief/medicaid-financing-the-basics	33
ERIN H. WARD, KEVIN J. HICKEY & KEITH T. RICHARDS, CONG. RSCH. SERV., R46679, <i>DRUG PRICES: THE ROLE OF PATENTS AND REGULATORY EXCLUSIVITIES</i> 12-14 (2021).....	25
Gabrielle Clerveau, et al., <i>A Snapshot of Sources of Coverage Among Medicare Beneficiaries</i> , KAISER FAMILY FOUNDATION (Aug. 14, 2023), https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries	27
Gabrielle Clerveau, et al., <i>supra</i> n.87. <i>MACPAC Releases 2022 Edition of MACStats: Medicaid and CHIP Data Book</i> , MACPAC (Dec. 15, 2022), https://www.macpac.gov/news/macpac-releases-2022-edition-of-macstats-medicare-and-chip-data-book	32

Health Insurance Coverage of the Total Population, KAISER FAMILY FOUNDATION (2021), <https://www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D>.....32

John N. Drobak, *From Turnpike to Nuclear Power: The Constitutional Limits on Utility Rate Regulation*, 65 B.U. L. REV. 65, 125 (1985).....29

Judie Svihula, *Political Economy, Moral Economy and the Medicare Modernization Act of 2003*, 35 J. SOCIO & SOC. WELFARE 157, 161 (2008).....11

Juliette Cubanski & Tricia Neuman, *What to Know About Medicare Spending and Financing*, KAISER FAMILY FOUNDATION (Jan. 19, 2023), <https://www.kff.org/medicare/issue-brief/what-to-know-about-medicare-spending-and-financing>32

Leah Z. Rand & Aaron S. Kesselheim, *Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries*, PHARMACOECONOMICS, Sept. 11, 2022.....21

Medicare Part B Drug Average Sales Price (Sept. 6, 2023 4:51 PM), <https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price>.....27

Mike McCaughan, *Veterans Health Administration*, HEALTH AFFAIRS (Aug. 10, 2017), <https://www.healthaffairs.org/doi/10.1377/hpb20171008.000174/>;32

NHE Fact Sheet, CMS.GOV, <https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet>33

Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Is Extending Monopolies and Driving Up Drug Prices, I-MAK 6–8 (Aug. 2018), <https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf>25

<i>Patients by TRICARE plan</i> , HEALTH.MIL, https://www.health.mil/Military-Health-Topics/MHS-Toolkits/Media-Resources/Media-Center/Patient-Population-Statistics/Patients-by-TRICARE-Plan ;	32
Ryan Conrad & Randall Lutter, <i>Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices</i> , U.S. FOOD & DRUG ADMIN. 2-3 (Dec. 2019).	25
Sean Dickson & Jeromie Ballreich, <i>How Much Can Pharma Lose? A Comparison of Returns Between Pharmaceutical and Other Industries</i> , WESTHEALTH POL'Y CTR. 3 (2019)	11, 20
Thomas W. Merrill, <i>Constitutional Limits on Physician Price Controls</i> , 21 HASTINGS CONST. L.Q. 635, 639 (1994).	30
U.S. Congressional Budget Office, Letter to Chairman Arrington and Congressman Burgess on Additional Information About Drug Price Negotiation and CBO's Simulation Model of Drug Development, at 4–5 (Dec. 21, 2023), https://www.cbo.gov/system/files/2023-12/59792-Letter.pdf .	12
U.S. GOV'T ACCOUNTABILITY OFF., GAO-21-111, PRESCRIPTION DRUGS: DEPARTMENT OF VETERANS AFFAIRS PAID ABOUT HALF AS MUCH AS MEDICARE PART D FOR SELECTED DRUGS IN 2017 (Dec. 15 2020)	28
U.S. GOV'T ACCOUNTABILITY OFF., GAO-23-105270, MEDICARE PART D: CMS SHOULD MONITOR EFFECTS OF REBATES ON PLAN FORMULARIES AND BENEFICIARY SPENDING (September 2023)	27

IDENTITY AND INTERESTS OF PROPOSED AMICUS CURIAE¹

Amici are law professors and scholars who focus their scholarship and teaching on intellectual property law, property law, regulatory law, and health law.² They write to address the plaintiffs', Bristol Myers Squibb (BMS) and Janssen Pharmaceuticals Inc. (Janssen), contention that the Medicare drug price negotiation program effectuates a taking of personal property in violation of the Fifth Amendment. Amici submit this brief to provide the Court with the historical and legal background necessary to understand the constitutionality of government price negotiations and price regulations. The amici explain how Courts have historically ruled on these questions, as well as the far-reaching consequences that a ruling in BMS and Janssen's favor would have on the federal government's ability to provide adequate healthcare across the United States.

I. INTRODUCTION

Today, about three in ten Americans cannot afford their prescription drugs.³

¹ No counsel for any party authored this brief in whole or in part. No entity or person, aside from amicus curiae, its members, or its counsel, made any monetary contribution intended to fund the preparation or submission of this brief. The parties have consented to the filing of this brief.

² Four professors in particular have guided the research, drafting, and editing of this brief: Amy Kapczynski, Christopher J. Morten, Aaron S. Kesselheim, & Ameet Sarpatwari.

³ Ashley Kirzinger et al., *Public Opinion on Prescription Drugs and Their Prices*, THE KAISER FAMILY FOUNDATION (Aug. 21, 2023),

High prices also drive-up insurance premiums and public spending, diverting resources from other priorities. The most decisive driver of high drug prices are the monopoly rights that governments grant to drug makers, allowing them to exclude competitors and raise prices.⁴ Responding to this deadly dilemma, Congress in 2022 passed the Inflation Reduction Act (IRA) and, with it, the Medicare drug price negotiation program.

This new program enables the Department of Health and Human Services, through the Centers for Medicare & Medicaid Services (CMS), to negotiate with drug makers over the prices of a small number of drugs that the Medicare program purchases. The IRA modifies a provision of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003—the “non-interference” provision—that prevented the federal government from negotiating the prices of retail medicines it buys via Part D insurance plans that operate its Medicare Part D program. This non-interference provision—a product of extensive pharmaceutical

<https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/>.

⁴ Aaron S. Kesselheim, Michael S. Sinha & Jerry Avorn, *Determinants of Market Exclusivity for Prescription Drugs in the United States*, 177 (11) JAMA INTERNAL MED. 1 (2017); Aaron S. Kesselheim, Jerry Avorn & Ameet Sarpatwari, *The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform*, 316 (8) JAMA 858 (2016).

lobbying⁵—has been anomalous since its inception. The federal government negotiates prices and receives discounts on most contracts it enters, including for drugs it purchases for patients covered by the Veterans Health, Section 340B, and Medicaid programs. Yet, it is forbidden from doing the same for Medicare. The IRA’s Medicare drug price negotiation program simply seeks to bring Medicare in line with the other government-sponsored insurance programs, for a limited number of high-revenue drugs, many years after their makers put them on the market.

BMS and Janssen argue that they have a constitutional right to the monopoly prices they have been charging the government. Pharmaceutical companies enjoy some of the highest profit margins in the United States—and will continue to do so despite this program.⁶ But this reality does not endow them with a Fifth

⁵ See Judie Svihula, *Political Economy, Moral Economy and the Medicare Modernization Act of 2003*, 35 J. SOCIO & SOC. WELFARE 157, 161 (2008); *Drug Industry and HMOs Deployed an Army of Nearly 1,000 Lobbyists to Push Medicare Bill, Report Finds*, PUB. CITIZEN (June 23, 2004), <https://www.citizen.org/news/drug-industry-and-hmos-deployed-an-army-of-nearly-1000-lobbyists-to-push-medicare-bill-report-finds>.

⁶ See Sean Dickson & Jeromie Ballreich, *How Much Can Pharma Lose? A Comparison of Returns Between Pharmaceutical and Other Industries*, WESTHEALTH POL’Y CTR. 3 (2019) (“[L]arge pharmaceutical manufacturers could endure significant revenue reductions . . . and still achieve the highest returns of any market sector.”); see e.g., Deena Beasley, *U.S. Will Still Pay at Least Twice as Much After Negotiating Drug Prices*, Reuters (Sept. 3, 2024), <https://www.reuters.com/world/us/us-will-still-pay-least-twice-much-after->

Amendment *right* to a certain price or level of profits when negotiating with the federal government for the purchase of goods—especially when those profits drain the public fisc, directly harm millions of Americans, and flow from government-granted privileges.⁷

The government may negotiate the prices of goods it purchases. The courts have long recognized that the federal government, like any private party, is authorized to negotiate the prices of the goods it purchases without running afoul of the Takings Clause. There is no constitutional entitlement to government

negotiating-drug-prices-2024-09-03/ (Affirming that the U.S. government’s negotiated prices for prescription drugs under the IRA are still on average more than double what is paid in high-income countries such as Australia, Japan, Canada, and Sweden); *see also* U.S. Congressional Budget Office, Letter to Chairman Arrington and Congressman Burgess on Additional Information About Drug Price Negotiation and CBO’s Simulation Model of Drug Development, at 4–5 (Dec. 21, 2023), <https://www.cbo.gov/system/files/2023-12/59792-Letter.pdf> (Reporting to the U.S. House of Representatives Committee on the Budget that despite claims that the implementation of the IRA would stifle innovation and significantly impact profit margins, there has been consistent and continuous increase in venture capital investment in pharmaceutical companies).

⁷ *See Boehringer Ingelheim Pharms., Inc. v. HHS*, No. 3:23-cv-1103, 2024 WL 3292657 (D. Conn. July 3, 2024) (Rejecting Boehringer’s argument that the IRA constitutes an unjustified taking pursuant to the Fifth Amendment); *AstraZeneca Pharms. LP v. Becerra*, No. 23-cv-00931, 2024 WL 895036, at *16 (D. Del. Mar. 1, 2024) (holding that because “AstraZeneca’s participation in Medicare is not involuntary, AstraZeneca does not have a protected property interest in selling drugs to the Government at prices the Government will not agree to pay. Accordingly, AstraZeneca’s due process claim fails as a matter of law.”); *see also Dayton Area Chamber of Com. v. Becerra*, No. 2:23 CV 156, 2024 WL 3741510 (S.D. Ohio Aug. 8, 2024) (dismissed on standing but raising similar arguments).

purchase of goods at prices a seller unilaterally dictates. BMS and Janssen understand this: they voluntarily participate in the Veterans Health, Section 340B, and Medicaid programs, each of which requires them to negotiate prices and offer price discounts. This rule alone settles the question this case presents. Price negotiations that discipline public spending do not give rise to a constitutional claim.

The government may regulate prices within an industry. BMS and Janssen also imply that the Medicare drug pricing negotiation program violates the Takings Clause because they have no realistic option but to participate in it due to the size of the Medicare market and the take-or-leave-it nature of the program. That too is false. The government holds the power to *set* prices in an industry like this one, without interference from the Takings Clause. Precedent teaches that price regulations are particularly justified and do not implicate the Takings Clause in industries that receive significant government privileges and are highly regulated. Here, drug makers' sales of patented and FDA-approved medicines meet both conditions. First, government-granted privileges, such as patents, data exclusivities, and tax credits, drive the profitability of the pharmaceutical industry. Second, the healthcare and pharmaceutical industry is arguably the most regulated in the country. As a result, Congress's authority to control drug prices extends far beyond that which the IRA achieves: even a mandatory price regulation affecting

all drugs the industry sells, not just those purchased by Medicare, would be constitutional.

Finding a taking here would unravel the principal government healthcare programs. Finally, accepting BMS and Janssen’s position would have far reaching ramifications for access to healthcare within the United States. Such a ruling would not only jeopardize the continued operation of the Medicare program, but also undermine the cost containment measures—price negotiations—that enable the Medicaid and Veterans Health programs to function. Indeed, when raised, courts have uniformly rejected Taking Clause challenges to the price negotiations in these programs. This Court should follow suit and decline to overturn decades of settled precedent.

The amici request that this Court affirm the lower court’s decision.

II. PROCEDURAL HISTORY

In June and July 2023, BMS and Janssen filed lawsuits against the CMS for, among other things, violating the Fifth Amendment as an unconstitutional taking of physical property.⁸ Parties filed cross motions for summary judgment and on April 29, 2024. The district court denied both BMS’s and Janssen’s motions and

⁸ Order re Summary Judgment, *Bristol Myers Squibb Co. v. Becerra*, No 23-cv-03818 (D.N.J.), *Janssen Pharm. Inc. v. Becerra*, 23-cv-03818, (D.N.J.), ECF 98, at 3.

granted CMS’s motion for summary judgment. In relevant part, the Court held the IRA does not violate the Fifth Amendment because the program is not a physical taking and both BMS’s and Janssen’s participation in Medicare is voluntary.⁹ BMS and Janssen appealed on April 29, 2024.¹⁰

III. ARGUMENT

A. **The government can, and routinely does, negotiate to form contracts for goods and services, including drugs, without implicating the Takings Clause.**

Courts have consistently held that “no one has a ‘right’ to sell to the government that which the government does not wish to buy.”¹¹ The government, “just like any other party participating in an economic market, is free to engage in the efficient procurement and sale of goods and services.”¹² To assist in this “efficient procurement,” the government holds the authority to (1) “determine those with whom it will deal,”¹³ (2) “fix the terms and conditions upon which it

⁹ Order, at 10, 18.

¹⁰ Appellant Opening Brief, *Bristol Myers Squibb Co. v. Becerra*, No. 24-1820 (3d Cir) ECF 27, at 13, 25, 38 (BMS App. Br.); Appellant Opening Brief, *Janssen Pharm. Inc. v. Becerra*, No. 24-1821 (3d Cir), at 23, 39, 51.

¹¹ *Coyne-Delany Co. v. Cap. Dev. Bd.*, 616 F.2d 341, 342 (7th Cir. 1980).

¹² *Associated Builders & Contractors Inc. v. City of Jersey City*, 836 F.3d 412, 417-18 (3d Cir. 2016).

¹³ *Perkins v. Lukens Steel Co.*, 310 U.S. 113, 127 (1940). See *J.H. Rutter Rex Mfg. Co. v. United States*, 706 F.2d 702, 712 (5th Cir. 1983) (rejecting government contractor’s claim for “Fifth Amendment property entitlement to participate in the

will make needed purchases,”¹⁴ and (3) negotiate the prices it will pay for goods and services.¹⁵ Such contracting does not implicate the Takings Clause. The federal government contracts in its commercial, not sovereign, capacity.¹⁶ In so doing, the government “removes itself from the ambit of the Fifth Amendment as ‘a takings claim cannot be based on the Government’s acting in its proprietary capacity.’”¹⁷

Yet, BMS and Janssen seek a constitutional right to sell their drugs at profits levels they dictate—levels that routinely exceed those in all other industries.¹⁸ BMS and Janssen claim that the IRA’s Medicare drug price negotiation program is a per se taking of their patented drugs. Yet they can point to no reassignment of patent rights or warehouse seizure of Eliquis tablets or Xarelto pills. Instead, BMS’s concession—that “seizing 50% of a company’s inventory is no different

awarding of government contracts”); *Curtiss-Wright Corp. v. McLucas*, 364 F. Supp. 750, 754 (D.N.J. 1973).

¹⁴ *Perkins*, 310 U.S. at 127.

¹⁵ *See Honolulu Rapid Transit Co. v. Dolim*, 459 F.2d 551, 553 (9th Cir. 1972) (“[T]he Supreme Court has left no doubt that the Federal Government enjoys power to conclude commercial bargains” (citing *Albrecht v. United States*, 329 U.S. 599, 603-04 (1947))); *see also* Price Negotiation, 48 C.F.R. § 15.405 (2022).

¹⁶ *See Hughes Commc'ns Galaxy, Inc. v. United States*, 271 F.3d 1060, 1070 (Fed. Cir. 2001); *St. Christopher Assocs., L.P. v. United States*, 511 F.3d 1376, 1385 (Fed. Cir. 2008).

¹⁷ *Klump v. United States*, 50 Fed. Cl. 268, 272 (2001) (citation omitted), *aff'd*, 30 F. App'x 958 (Fed. Cir. 2002). Contractors’ remedies for breach of contract are based on the contract, not based on constitutional rights. *See Hughes Commc'ns*, 271 F.3d at 1070.

¹⁸ *See supra* n.6.

from seizing that inventory at a 50% discount”¹⁹—reveals that the true “taking” at issue is profit reduction.

There is no right to a fixed level of profits. The government frequently negotiates prices before entering contracts. In 2022, the government spent \$694 billion on contracts.²⁰ Many of these contracts were fixed-price vehicles that do not guarantee or even encourage profit.²¹ The IRA’s drug price negotiation program is simply another example of the government negotiating with a private vendor in a commercial capacity to purchase goods.

In fact, the government *already negotiates* drug prices and sets parameters on the prices it will pay for drugs across several federal programs, including the Veterans Health Administration, Section 340B, and Medicaid programs.²² Each program has a baseline statutory discount with options for the federal government or seller (e.g., a hospital) to negotiate further discounts.²³ Drug makers do not have

¹⁹ BMS App. at 17.

²⁰ See *A Snapshot: Government-Wide Contracting*, GOVERNMENT ACCOUNTABILITY OFFICE (May 2023), https://gaoinnovations.gov/Federal_Government_Contracting.

²¹ *Id.* (noting that majority of contracts awarded in fiscal year 2022 were fixed price); *United States v. White*, 765 F.2d 1469, 1472 (11th Cir. 1985).

²² See 38 U.S.C. § 8126 (Veterans Health Administration); 42 U.S.C. §§ 256b (Section 340B), 1396r-8 (Medicaid).

²³ See 38 U.S.C. § 8126(a)(2); 42 U.S.C. § 256b(a)(1), (10); 42 U.S.C. §§ 1396r-8(a) (requiring drug manufacturer to “have in effect a rebate agreement” with HHS); (c)(1).

to supply medicines to the government. However, if they opt not to sell to the Veterans Health Administration or the 340B program, the government can limit the drug maker's access to Medicaid (and by extension, Medicare Part B).²⁴ These programs offer manufacturers the opportunity to negotiate drug prices in exchange for access to various government markets.

Courts have routinely and uniformly held that the structure and requirements of these programs do not effectuate a taking. For example, courts have emphasized that the 340B program is voluntary, even if withdrawal from one program means the drug company will be prohibited from selling its drugs to another government program.²⁵ “[E]conomic hardship is not equivalent to legal compulsion for

²⁴ See 38 U.S.C. § 8126(a)(4); 42 U.S.C. §§ 1396r-8(a)(1), (a)(5)(A). See also *Eli Lilly & Co. v. United States Dep't of Health & Human Servs.*, No. 21-cv-00081, 2021 WL 5039566, at *2 (S.D. Ind. Oct. 29, 2021) (340B program “requires, as a condition of Plaintiffs' participation in Medicaid and Medicare Part B, that pharmaceutical manufacturers such as Plaintiffs sell their outpatient drugs at a heavily discounted price to “covered entities”).

²⁵ See *Sanofi-Aventis U.S., LLC v. U.S. Dep't of Health & Hum. Servs.*, 570 F. Supp. 3d 129, 209-10 (D.N.J. 2021), *aff'd in part, rev'd in part sub nom. Sanofi Aventis U.S. LLC v. United States Dep't of Health & Hum. Servs.*, 58 F.4th 696 (3d Cir. 2023), *judgment entered*, No. 21-3167, 2023 WL 1325507 (3d Cir. Jan. 30, 2023); *Eli Lilly & Co.*, 2021 WL 5039566, at *21.

purposes of takings analysis.”²⁶ Indeed, one court described the manufacturers’ per se physical takings argument in a 340B case as borderline nonsensical.²⁷

The IRA’s Medicare drug price negotiation program sets up a structure similar to the existing drug purchase programs under 340B, Medicaid, and the Veterans Health Administration.²⁸ The takings analysis here should not differ. Accepting BMS and Janssen’s argument that price negotiations constitute a taking would open the door for nearly all contract negotiations and “[g]overnment contract breaches [to] give rise to compensation under the Fifth Amendment.”²⁹ Such a view would not only undermine settled contract law involving voluntary, bargained-for exchanges, but also upend hundreds of government contracts at an industry’s whim.

²⁶ *Eli Lilly & Co.*, 2021 WL 5039566 at *21 (quoting *Garelick v. Sullivan*, 987 F. 2d 913 (2d Cir. 1993)) (quotations omitted).

²⁷ *See Sanofi-Aventis*, 570 F. Supp. 3d at 208 (“Such an argument makes little sense given how the 340B Program works. HHS does not acquire title to Sanofi’s drugs. . . obtain them for a third party. . . or compel Novo to surrender them [T]here is no ‘government-authorized invasion.’”) (quoting *Cedar Point Nursery v. Hassid*, 141 S. Ct. 2063, 2074 (2021)).

²⁸ *See* P.L. 117-169, § 11101 (enacted in Aug. 2022).

²⁹ *See Hughes Commc'ns*, 271 F.3d at 1070.

B. Congress has the authority to regulate drug prices directly, and even a price regulation applied to the whole pharmaceutical industry would be constitutional.

1. Price regulation in the pharmaceutical industry is particularly justified—and does not implicate the Takings Clause—because the industry is supported by many government privileges, subject to significant monopoly pricing problems, and highly regulated.

Price regulations achieve the “broad societal interest” of “protecting consumers from excessive prices.”³⁰ Price regulation is particularly justified and does not implicate the Takings Clause in industries that (1) benefit from significant government privileges and (2) are highly regulated. The sales of medicines within the pharmaceutical industry to the government meet both conditions. Myriad government-granted privileges—in the form of monopoly power, tax credits, and research funding—have made the pharmaceutical industry one of the most profitable in the world.³¹ The pharmaceutical industry is also highly regulated. And caselaw affirms Congress’s authority and special latitude to impose conditions on industries that benefit from such government privileges and regulations. As such, Congress could lawfully implement a price regulation affecting *all* drugs on the market, not just those sold to Medicare.³² Here, the Medicare drug price

³⁰ *Exxon Corp. v. Eagerton*, 462 U.S. 176, 190-91 (1983) (internal citation and quotations omitted).

³¹ See *Dickson & Ballreich*, *supra* n.6.

³² Even BMS conceded that “price caps” on drugs would not pose constitutional

negotiation program, even if viewed as a mandatory price regulation, survives any takings challenge.³³

Where the federal government grants an individual or industry a special privilege, it is entitled to impose conditions thereon. *And such conditions do not give rise to takings claims.* The Supreme Court affirmed this principle in *Leonard v. Earle*.³⁴ In 1929, *Leonard* affirmed that a Maryland law requiring oyster packers to give the state ten percent of their collected oyster shells—a valuable commodity—did not constitute a takings.³⁵ Even where the oysters had been “taken and reduced to possession by an individual,” the Court held that the packer’s “ownership may be regulated and restrained by appropriate legislation enacted for considerations of state or the benefit of the community.”³⁶

issues: “Congress could have . . . unilaterally impose[d] price caps that Medicare would pay for covered medicines.” Compl. ¶ 82, *Bristol Myers Squibb Co. v. Becerra*, Civ. A. No. 23-3335, ECF No. 1 (D.N.J. June 16, 2023); *see also* BMS App. Br. at 16.

³³ Price negotiation and regulation of medicines is the norm among peer nations. *See, e.g.,* Leah Z. Rand & Aaron S. Kesselheim, *Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries*, PHARMACOECONOMICS, Sept. 11, 2022.

³⁴ *Leonard v. Earle*, 279 U.S. 392 (1929).

³⁵ *Id.* at 394, 396, 398; *Leonard v. Earle*, 141 A. 714, 715-16 (1928), *aff’d*, 279 U.S. 392 (1929). *See Horne v. Dep’t of Agric.*, 576 U.S. 350, 366-67 (2015) (describing both decisions).

³⁶ *Leonard*, 141 A. at 716.

The Supreme Court’s recent decision in *Horne v. Department of Agriculture*—BMS and Janssen’s principal authority—did not disturb *Leonard*—it affirmed *Leonard’s* logic.³⁷ As *Horne* explained, “[t]he oysters, unlike raisins, were ‘feræ naturæ’ that belonged to the State under state law, and “[n]o individual ha[d] any property rights in them other than such as the state may permit him to acquire.”³⁸ The same can be said of patented medications: no individual holds a right to a patent “other than such as the state may permit him to acquire.”³⁹ And without patents, brand manufacturers like BMS and Janssen would lose the power to reap the benefit—high profits—they contend has been taken by the Medicare drug price negotiations.

Over fifty years after *Leonard*, in *Ruckelshaus v. Monsanto*, the Supreme Court reiterated the government’s authority to set conditions on the benefits of market access it bestows on regulated companies.⁴⁰ There, the Court considered, *inter alia*, (1) whether the appellee, Monsanto, had “a property interest” “protected by the Fifth Amendment’s Taking Clause in the health, safety, and environmental data” it submitted to the Environmental Protection Agency (EPA) under the

³⁷ *Horne*, 576 U.S. at 366-67.

³⁸ *Id.* at 367.

³⁹ *Id.*; see U.S. Const. Art. I § 8, Cl. 8 (Congress hold the power—but the not the obligation—to grant patents).

⁴⁰ *Ruckelshaus v. Monsanto Co.*, 467 U.S. 986 (1984).

Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA); and (2) if so, whether the EPA’s competitive use or disclosure of that data constituted a taking.⁴¹

As to the first question, the Supreme Court noted that the state conceded that the data was “cognizable as a trade-secret property right under Missouri law,” and concluded that trade secrets could be protectable property interests under the Takings Clause.⁴² As to the second, the Court concluded that Monsanto’s “voluntary submission of data . . . in exchange for the economic advantages of a registration can hardly be called a taking.”⁴³ As articulated in *Horne*, Monsanto and other similarly situated insecticide manufacturers “were not subjected to a taking because they received a ‘valuable Government benefit’ in exchange—a license to sell dangerous chemicals.”⁴⁴ Not only were the companies seeking licenses to sell insecticides required to share certain information with the government, but the government was also entitled to give that information to the public. Thus, the government is free to impose conditions on the benefits it gives; doing so is not a taking.

⁴¹ *Id.* at 1000.

⁴² *Id.* at 1003-04.

⁴³ *Id.* at 1006-07 (concluding Monsanto was “aware of the conditions under which the data are submitted, and the conditions are rationally related to a legitimate Government interest”).

⁴⁴ *Horne*, 576 U.S. at 365-66.

The pharmaceutical regulatory system is on all fours with the regulation of insecticides in *Monsanto*. Just as the EPA regulates the issuance of a “license to sell dangerous chemicals,”⁴⁵ the FDA regulates the sale of pharmaceuticals, requiring manufacturers to apply, submit safety and efficacy clinical trial data, and receive FDA approval before marketing their (potentially dangerous) drugs.⁴⁶ By granting a pharmaceutical company’s new drug application, the FDA grants a “valuable Government benefit”⁴⁷—permission to sell the drug. In exchange, the federal government is free to impose conditions and regulations without violating the Taking Clause.

The government also grants drug makers significant benefits that enable their high prices and profits throughout drug development, manufacturing, and sales. First, the government subsidizes new drug development through tax credits and the direct funding of disease and drug research via the National Institutes of Health, among other mechanisms.⁴⁸ Next, the FDA’s licensing requirements—

⁴⁵ *Id.*

⁴⁶ *Cf. Id.* at 366 (distinguishing *Monsanto*: “Raisins are not dangerous pesticides; they are a healthy snack. A case about conditioning the sale of hazardous substances on disclosure of health, safety, and environmental information related to those hazards is hardly on point.”).

⁴⁷ *Monsanto*, 467 U.S. at 1007.

⁴⁸ See David Austin & Tamara Hayford, *Research & Development in the Pharmaceutical Industry* 18-20, CONG. BUDGET OFF. (2021); Ekaterina Galkina Cleary, Matthew J. Jackson, Edward W. Zhou & Fred D. Ledley, *Comparison of*

demanding submission of clinical trial data—create barriers to entry, limiting the number of competitors that can enter the market.

Concurrent patent and regulatory exclusivities then permit the approved drug makers to exclude others from the market, setting prices far above those they could obtain in the face of generic competition and the average and marginal cost of manufacturing their medications.⁴⁹ In addition to the twenty-year term of patent exclusivity a manufacturer usually obtains on its drug’s active ingredient, pharmaceutical companies frequently obtain a range of “secondary” patents that further extend the pharmaceutical company’s monopoly.⁵⁰

Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019, 4 JAMA HEALTH F. 1, 1 (2023) (finding that between 2010 and 2019, NIH provided funding that contributed to almost every drug approved during that period).

⁴⁹ According to the FDA, where only one generic is allowed onto the market, that generic will price its competitor product 39% lower than the brand, on average; with six or more generic drugs on the market, the discount off the brand-drug price increases to 95%. Ryan Conrad & Randall Lutter, *Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices*, U.S. FOOD & DRUG ADMIN. 2-3 (Dec. 2019). See ERIN H. WARD, KEVIN J. HICKEY & KEITH T. RICHARDS, CONG. RSCH. SERV., R46679, DRUG PRICES: THE ROLE OF PATENTS AND REGULATORY EXCLUSIVITIES 12-14, 29 (2021).

⁵⁰ See *Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Is Extending Monopolies and Driving Up Drug Prices*, I-MAK 6–8 (Aug. 2018), <https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf> (finding the top 12 drugs by gross U.S. revenue were associated with an average of 71 patents each); Amy Kapczynski, Chan Park & Bhavan Sampat, *Polymorphs and Prodrugs and Salts (Oh My!): An Empirical*

In addition to these exclusivities, statutory purchasing obligations for Medicare and other federal prescription drug programs guarantee drug makers a robust market. The statutes establishing Medicaid, Medicare, Section 340B, and the Veterans Administration drug program *require* the federal government to purchase or otherwise provide drugs for each program’s beneficiaries.⁵¹ Other laws and regulations require government insurance programs to cover certain classes of drugs, including many branded pharmaceuticals.⁵²

The protections and benefits the government grants to the pharmaceutical industry permit the former great latitude to regulate the fruits of the latter—i.e., medicines. Such price regulation is not only authorized by Congress and the courts, but it also provides essential benefits to the public at large. Indeed, without price regulation in this setting, we face a predictable problem of high—and rising—monopoly prices, unjustified by investment, that put patients and the system at risk.

An apt example is Medicare without the IRA’s drug price negotiation program. Medicare makes up the largest portion of the federal government’s drug

Analysis of “Secondary” Pharmaceutical Patents, 7 PLOS ONE 1, 6-7 (2012) (secondary patents extend market exclusivity by several years).

⁵¹ *See* 42 U.S.C. § 1396d(12); 42 U.S.C. § 256b(1) (“The Secretary shall . . .”); 42 U.S.C. § 1395w-3b; 42 U.S.C. § 1395w-101(a)(1) (“[E]ach part D eligible individual . . . is entitled to obtain qualified prescription drug coverage”); 38 U.S.C. § 8126(a).

⁵² *See, e.g.*, 42 U.S.C. §§ 1395w-102, 104(b)(3) (describing general Part D formulary requirements); 42 C.F.R. § 423.120 (2024); 42 U.S.C. § 1396r-8(d)(1).

purchase obligation: the program’s current regulatory structures require the government to provide coverage for pharmaceuticals, where prescribed, to a market of 65 million people.⁵³ In 2021, Medicare Part D spending exceeded \$200 billion.⁵⁴ And this figure continues to rise.⁵⁵ Despite this spending, as noted above, consumers in this program struggle to pay for drugs.⁵⁶ The program currently has no structural price controls and, without the IRA’s drug price negotiation program, limited negotiating power.⁵⁷ Medicare Part B does not negotiate at all, paying for drugs at the average sales price in the private market, plus 6%.⁵⁸ With no ability to

⁵³ See Gabrielle Clerveau, et al., *A Snapshot of Sources of Coverage Among Medicare Beneficiaries*, KAISER FAMILY FOUNDATION (Aug. 14, 2023), <https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries>.

⁵⁴ See U.S. GOV’T ACCOUNTABILITY OFF., GAO-23-105270, *MEDICARE PART D: CMS SHOULD MONITOR EFFECTS OF REBATES ON PLAN FORMULARIES AND BENEFICIARY SPENDING* (September 2023).

⁵⁵ See *Baseline Projections: Medicare*, CONG. BUDGET OFF. (May 2023); see also David Austin & Tamara Hayford, *Prescription Drugs: Spending, Use, and Prices* 8, CONG. BUDGET OFF. (Jan. 2022).

⁵⁶ See discussion *supra* in Introduction.

⁵⁷ See 42 U.S.C. § 1395w-101(a)(1) (2018).

⁵⁸ See *Medicare Part B Drug Average Sales Price*, CMS.GOV (Sept. 6, 2023 4:51 PM), <https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price>. Medicare Part B is Medicare’s medical insurance benefit. In addition to physician visits and hospital services, it often covers drugs that must be administered in an in-patient setting.

negotiate, the government and seniors—via the Medicare program—are held hostage by drug makers’ high prices (and profits).⁵⁹

The Supreme Court has held that in highly regulated industries, especially where price regulations are present in some domains, the “foreseeab[ility]” of price regulations negates certain constitutional claims.⁶⁰ The pharmaceutical industry is arguably the most regulated industry in the country, and government price negotiations and regulations are part and parcel of federal healthcare programs, including through the Veterans Health Administration, Section 340B, and Medicaid programs.

⁵⁹ See 42 U.S.C. § 1395w-111 (2018); U.S. GOV’T ACCOUNTABILITY OFF., GAO-21-111, PRESCRIPTION DRUGS: DEPARTMENT OF VETERANS AFFAIRS PAID ABOUT HALF AS MUCH AS MEDICARE PART D FOR SELECTED DRUGS IN 2017 (Dec. 15 2020) (“Department of Veterans Affairs (VA) paid, on average, 54 percent less per unit for a sample of 399 brand-name and generic prescription drugs in 2017 as did Medicare Part D, even after accounting for applicable rebates and price concessions in the Part D program.”); see also Aaron S. Kesselheim, Jerry Avorn, & Ameet Sarpatwari, *The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform*, 316 J. AM. MED. ASS’N 858 (2016) (noting that U.S. drug prices are not based on the price of research and development, but instead on what the market will bear).

⁶⁰ See, e.g., *Energy Reserves Group, Inc. v. Kansas Power and Light Co.*, 459 U.S. 400, 413, 416, 419 (1983) (concluding that in a “heavily regulated industry,” price regulation was “foreseeable as the type of law that would alter contract obligations” and was constitutionally permissible under Contracts Clause). See also *74 Pinehurst LLC v. New York*, 59 F.4th 557, 567-68 (2d Cir. 2023) (holding that because a “reasonable investor” in the housing market “would have anticipated [that] their rental properties would be subject to regulation”—because of the expansive “regime of rent regulations”—price controls “result[ing] in a loss does not constitute a taking”).

In sum, even if applied to the entire pharmaceutical industry, which this *Medicare* drug price negotiation program is not, price regulation would be justified. It would not implicate the Takings Clause because it would not “unfairly single[] out the property owner to bear a burden that should be borne by the public as a whole.”⁶¹

2. There is no legal mandate to sell medicines, and even if there were, only a minimal “just compensation” requirement would apply.

In certain industries, the government legally *mandates* that a seller serve the market at fixed prices. Historically, courts have exercised some judicial oversight over those rates, but that oversight is the exception, not the rule.⁶² In recent years, caselaw requiring just compensation for such services pertains only to rate-regulated utilities. This is because utility providers are *required*, by law, to serve

⁶¹ *Yee v. City of Escondido, Cal.*, 503 U.S. 519, 522-23 (1992).

⁶² *See, e.g., Hegeman Farms v. Baldwin*, 293 U.S. 163 at 170 (1934) (“The appellant would have us say that . . . [a government-regulated price] must be changed whenever a particular dealer can show that . . . its application to himself is to deprive him of a profit. This is not enough to subject administrative rulings to revision by the courts.”); *Aetna Ins. Co. v. Hyde*, 275 U.S. 440, 447-48 (1928). *See generally* John N. Drobak, *From Turnpike to Nuclear Power: The Constitutional Limits on Utility Rate Regulation*, 65 B.U. L. REV. 65, 125 (1985) (“The Supreme Court has established a limited role for the judiciary in its constitutional review of [utility] ratemaking, consistent with the judiciary’s limited role in reviewing other kinds of economic regulation.”).

the market; they cannot pull out.⁶³ Pharmaceutical companies, by contrast, *voluntarily* choose to sell their drugs on the market, without any obligation to participate. As a result, they are not entitled to judicial oversight of government price regulations.⁶⁴

Even if the utility rule applied to pharmaceutical manufacturers, they would only be entitled to a “just and reasonable” compensation.⁶⁵ “Just and reasonable” compensation is a minimal standard for rate-setting.⁶⁶ Sellers are entitled to a rate

⁶³ See *Duquesne Light Co. v. Barasch*, 488 U.S. 299, 307 (1989); *Pittsburgh & Lake Erie R.R. Co. v. Ry. Labor Execs’ Ass’n*, 491 U.S. 490, 515 (1989) (Stevens, J., concurring) (“Regulated utilities do not have the same freedom to respond to market pressures that unregulated firms have. They may not raise rates or cut services . . . without permission from a regulatory agency . . . [and] they may neither enter nor leave the market without agency approval.”); see also Thomas W. Merrill, *Constitutional Limits on Physician Price Controls*, 21 HASTINGS CONST. L.Q. 635, 639 (1994) (“The Supreme Court has made it clear that the Takings Clause imposes significant limits on the power of government to regulate certain prices, most prominently, the rates charged by common carriers and public utilities. On the other hand, other types of price controls . . . have never been thought to raise questions under the Takings Clause.”).

⁶⁴ See *Yee*, 503 U.S. at 531 (“Because they voluntarily open their property to occupation by others, petitioners cannot assert a per se right to compensation based on their inability to exclude particular individuals”); *Price Administr. Bowles v. Willingham*, 321 U.S. 503, 517 (1944) (upholding World War II rent controls against takings challenge because statute did not require landlords “to offer any accommodations for rent”).

⁶⁵ See *Fed. Power Comm’n v. Hope Nat. Gas Co.*, 320 U.S. 591, 602-03 (1944).

⁶⁶ See *Duquesne*, 488 U.S. at 310-11; see also *id.* at 315-16 (“It has repeatedly been stated that no single method need be followed by the Commission in considering the justness and reasonableness of rates.’ . . . The designation of a single theory of ratemaking as a constitutional requirement would unnecessarily

that reflects their original capital investments and expenditures and allows them to reasonably attract future capital.⁶⁷ The complexity of making these determinations means that courts give the government discretion in setting rates, regardless of the methodology employed,⁶⁸ “if the total effect of the rate order cannot be said to be unreasonable.”⁶⁹ Such compensation certainly does not require that the regulated business earn a profit.⁷⁰

The Medicare drug price negotiation program is a *price* negotiation, not a rate negotiation.

foreclose alternatives which could benefit both consumers and investors.” (quoting *Wisconsin v. FPC*, 373 U.S. 294, 309 (1963)).

⁶⁷ See *Hope*, 320 U.S. at 602-03 (“[T]he return to the equity owner should be commensurate with returns on investments That return, moreover, should be sufficient to assure confidence in the financial integrity of the enterprise, so as to maintain its credit and to attract capital.”); see also *Duquesne*, 488 U.S. at 302, 312 (holding that a reduced rate did not constitute a takings and emphasizing that the challenger failed to argue the reduced rate “jeopardize[d] the financial integrity of the companies, either by leaving them insufficient operating capital or by impeding their ability to raise future capital.”).

⁶⁸ Boyd, *supra* note 40, at 767 (noting that after *Hope*, “in the vast majority of cases, the courts simply deferred to the commissions, no longer twisting themselves into knots trying to make the methods of valuation at the heart of ratemaking comport with received notions of property and its constitutional protections.”).

⁶⁹ *Duquesne*, 488 U.S. at 310 (quoting *Hope*, 320 U.S. at 602).

⁷⁰ See *Permian Basin Area Rate Cases*, 390 U.S. 747, 769 (1968) (“Regulation may, consistent with the Constitution, limit stringently the return recovered on investment.”); *Fed. Power Comm’n v. Sierra Pac. Power Co.*, 350 U.S. 348, 355 (1956) (holding that a rate “may not be said to be either ‘unjust’ or ‘unreasonable’ simply because it is unprofitable to the public utility”).

C. A ruling that the Medicare drug price negotiations constitute a per se taking would upend the Medicare, Medicaid, and Veterans Administration programs.

Federal and state healthcare programs provide a key safety net for more than one in three Americans.⁷¹ But, due to their reach, these programs strain state and federal budgets. In 2021, Medicare alone accounted for 21% of all U.S. healthcare spending and 10% of the federal budget.⁷² Medicare's costs are predicted to rise to 18% of the federal budget in 2032.⁷³ Medicaid cost \$728 billion, excluding

⁷¹ See *Health Insurance Coverage of the Total Population*, KAISER FAMILY FOUNDATION (2021), <https://www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D>. In 2017, the Veterans Health Administration provided care to 9 million veterans and their families. In 2022, TRICARE, DoD's insurance program, covered approximately 9.5 million service members and their families. Medicare covers 65 million people, and in 2022, Medicaid or CHIP covered almost 90 million Americans. See Mike McCaughan, *Veterans Health Administration*, HEALTH AFFAIRS (Aug. 10, 2017), <https://www.healthaffairs.org/doi/10.1377/hpb20171008.000174/>; *Patients by TRICARE plan*, HEALTH.MIL, <https://www.health.mil/Military-Health-Topics/MHS-Toolkits/Media-Resources/Media-Center/Patient-Population-Statistics/Patients-by-TRICARE-Plan>; Gabrielle Clerveau, et al., *supra* n.53. MACPAC Releases 2022 Edition of MACStats: Medicaid and CHIP Data Book, MACPAC (Dec. 15, 2022), <https://www.macpac.gov/news/macpac-releases-2022-edition-of-macstats-medicaid-and-chip-data-book>.

⁷² See Juliette Cubanski & Tricia Neuman, *What to Know About Medicare Spending and Financing*, KAISER FAMILY FOUNDATION (Jan. 19, 2023), <https://www.kff.org/medicare/issue-brief/what-to-know-about-medicare-spending-and-financing>.

⁷³ *Id.*

administrative costs, in fiscal year 2021,⁷⁴ about 17% of national health expenditures that year.⁷⁵

Price caps and negotiated discounts on healthcare services enable federal and state healthcare programs to offer coverage to millions of Americans. A ruling that these programs' statutory discounts constitute takings would imperil these programs' continued operation. For patients, this would translate into reduced access to healthcare. For courts, it would mean a flood of litigation over the level of payment necessary to compensate takings by voluntary and mandatory programs never-before questioned. Courts would be asked to take on the administrative role of rate-setter, weighing the cost and benefits of each government contract for healthcare services.

But the Medicare, Medicaid, and Veteran Health Administration programs would not be the only areas of healthcare affected. All Americans are entitled to emergency room treatment, irrespective of insurance status, based on the federal Emergency Medical Treatment and Labor Act (EMTALA). This law requires hospitals with emergency departments that receive Medicare funding to accept all

⁷⁴ See Elizabeth Williams et al., *Medicaid Financing: The Basics*, KAISER FAMILY FOUNDATION (Apr. 13, 2023), <https://www.kff.org/medicaid/issue-brief/medicaid-financing-the-basics>.

⁷⁵ See *NHE Fact Sheet*, CMS.GOV, <https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet>.

patients in critical condition, regardless of their ability to pay.⁷⁶ Takings challenges to EMTALA have failed on the grounds that participation in Medicare (and by extension in EMTALA) is voluntary.⁷⁷ A holding that the IRA’s Medicare drug price negotiations are coerced could open the door to a similar holding with respect to EMTALA. Every unpaid emergency room visit could be grounds for a takings lawsuit in which a court would have to evaluate the degree of government compensation necessary—an unimaginably complex task given the byzantine world of medical billing and government reimbursement rates.

IV. CONCLUSION

For these reasons, amici respectfully request that the Court affirm the District Court’s decision.

V. SIGNATORIES⁷⁸

Aziza Ahmed
Professor of Law
Boston University School of Law

⁷⁶ See 42 U.S.C. § 1395cc(a)(1)(I)(i); 42 U.S.C. § 1395dd.

⁷⁷ See, e.g., *Burditt v. U.S. Dep’t of Health & Hum. Servs.*, 934 F. 2d 1362, 1376 (5th Cir. 1991); *Baker Cnty. Med. Servs., Inc. v. U.S. Atty. Gen.*, 763 F. 3d 1274, 1279-80 (11th Cir. 2014) (quoting *Whitney*, 780 F.2d 963, 972 (“Just as physicians who voluntarily treat Medicare beneficiaries cannot establish the legal compulsion necessary to challenge Medicare reimbursement rates as a taking, so too is the Hospital precluded from challenging the rate at which it is compensated for its voluntary treatment of federal detainees, a regulated industry in which the Hospital as a ‘regulated group is not required to participate.’”).

⁷⁸ Institutional affiliations are provided for informational purposes only.

Brook K. Baker

Professor of Law
Northeastern University School of Law

Yochai Benkler

Jack N. and Lillian R. Berkman Professor for Entrepreneurial Legal Studies
Faculty Co-Director, Berkman Klein Center for Internet and Society
Harvard Law School

Scott Burris

Professor of Law and Public Health
Director, Center for Public Health Law Research
Temple University Beasley School of Law

Troyen Brennan

Adjunct Professor of Health Policy and Management
Harvard T. H. Chan School of Public Health

Michael A. Carrier

Board of Governors Professor
Co-Director, Rutgers Institute for Information Policy and Law
Rutgers Law School

Bernard Chao

Professor of Law
University of Denver Sturm College of Law

Jorge L. Contreras

James T. Jenson Endowed Professor for Transactional Law
Director, Program on Intellectual Property and Technology Law
Adjunct Professor of Human Genetics
University of Utah College of Law

Nathan Cortez

Co-Director of the Tsai Center for Law, Science and Innovation
Adelfa Botello Callejo Endowed Professor of Law in Leadership and Latino
Studies
Southern Methodist University Dedman School of Law

Stacey L. Dogan

Professor & Law Alumni Scholar
Boston University School of Law

Charles Duan

Assistant Professor of Law
American University Washington College of Law

Samuel F. Ernst

Associate Dean for Academic Affairs
Professor of Law
Golden Gate University School of Law

Robert I. Field

Professor of Law
Drexel University Kline School of Law
Professor of Health Management and Policy
Drexel University Dornsife School of Public Health

Sean Flynn

Professorial Lecturer of Intellectual Property and Human Rights
Director, Program on Information Justice and Intellectual Property
American University Washington College of Law

Lawrence O. Gostin

Founding O'Neill Chair in Global Health Law
Faculty Director, O'Neill Institute
Director, WHO Collaborating Center on Global Health Law
Georgetown Law

Peter Henderson

Incoming Assistant Professor
School of Public and International Affairs
Department of Computer Science
Princeton University

Laura Hermer

Professor of Law
Mitchell Hamline School of Law

Allison K. Hoffman

Deputy Dean, Professor of Law
University of Pennsylvania Penn Carey Law School

Nicole Huberfeld

Edward R. Utey Professor of Health Law & Professor of Law
Co-Director, Boston University Program on Reproductive Justice
Assistant Director, Center for Health Law, Ethics & Human Rights
Boston University School of Public Health
Boston University School of Law

Peter D. Jacobson

Professor Emeritus of Health Law and Policy
University of Michigan School of Public Health

Timothy S. Jost

Emeritus Professor of Law
Washington and Lee University School of Law

Amy Kapczynski

Professor of Law
Faculty Director of the Global Health Justice Partnership
Yale Law School

Aaron S. Kesselheim

Professor of Medicine
Harvard Medical School
Director of the Program on Regulation, Therapeutics, and Law
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital

Renee M. Landers

Professor of Law
Faculty Director, Health and Biomedical Law Concentration and Master of
Science in Law,
Life Science Program
Suffolk University Law School

Stacey M. Lantagne

Professor of Law

Western New England University School of Law

Mark A. Lemley

William H. Neukom Professor

Director, Stanford Program in Law, Science, and Technology

Stanford Law School

Senior Fellow, Stanford Institute for Economic Policy Research

Affiliated Professor, Stanford Symbolic Systems Program

Christopher J. Morten

Associate Clinical Professor of Law

Columbia Law School

Jordan Paradise

Georgia Reithal Professor of Law

Co-Director, Beazley Institute for Health Law and Policy

Loyola University Chicago School of Law

Wendy E. Parmet

Matthews University Distinguished Professor of Law and

Professor of Public Policy and Urban Affairs

Northeastern University

Srividhya Ragavan

Professor of Intellectual Property and International Trade Law

Director of International Programs

Texas A&M University School of Law

Arti Rai

Elvin R. Latty Professor

Faculty Direction, Center for Innovation Policy

Duke Law School

Christopher Robertson

Associate Dean for Strategic Initiatives

Professor of Health and Disability Law

Boston University School of Law

Professor of Health Law, Policy & Management

Boston University School of Public Health

Marc A. Rodwin

Professor of Health Law and Policy
Suffolk University Law School

Sara Rosenbaum

Professor of Emerita, Health Law and Policy
Milken Institute School of Public Health
George Washington University

Ana Santos Rutschman

Professor of Law
Charles Widger School of Law
Villanova University

Ameet Sarpatwari

Assistant Professor of Medicine,
Harvard Medical School
Assistant Director of the Program on Regulation, Therapeutics, and Law
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital

Cason Schmit

Assistant Professor
Director, Program in Health Law and Policy
Department of Health Policy & Management, School of Public Health
Texas A&M University

Jason M. Schultz

Professor of Clinical Law
Director of NYU's Technology and Policy Clinic
Co-Director of the Engelberg Center on Innovation Law & Policy
New York University School of Law

Jessica Silbey

Professor of Law and Yanakakis Faculty Research Scholar
Boston University School of Law
Affiliate Fellow, Information Society Project (ISP), Yale Law School
Affiliate Faculty, Center for Innovation in Social Sciences (CISS), Boston
University

Michael S. Sinha

Assistant Professor of Health Law and Intellectual Property Law
Center for Health Law Studies
Saint Louis University School of Law

Talha Syed

Lecturer on Intellectual Property, Torts and Antitrust Law
University of California Berkeley Law

S. Sean Tu

Arthur S. Dayton Professor of Intellectual Property and Food and Drug Law
West Virginia University College of Law

Michael R. Ulrich

Assistant Professor
Center for Health, Law, Ethics & Human Rights
Boston University School of Public Health
Boston University School of Law
Distinguished Visiting Scholar
Solomon Center for Health Law & Policy
Yale Law School

Liza Vertinsky

Professor of Law
University of Maryland Francis King Carey School of Law

Sidney Watson

Professor of Law and Scholar in Residence
Center for Health Law Studies
Saint Louis University School of Law

Rebecca Wolitz

Assistant Professor of Law
The Ohio State University Moritz College of Law

Peter K. Yu

Regents Professor of Law and Communication
Director, Center for Law and Intellectual Property
Texas A&M University

Esther van Zimmeren
Professor of Intellectual Property Law & Governance
University of Antwerp

Date: September 16, 2024

Respectfully submitted,

Hannah W. Brennan
Claudia Morera
Rebekah Glickman-Simon
Hagens Berman Sobol Shapiro LLP
One Faneuil Hall Sq., 5th Floor
Boston, MA 02109
Telephone: (617) 482-3700
Facsimile: (617) 482-3003
hannahb@hbsslaw.com
claudiam@hbsslaw.com
rebekahgs@hbsslaw.com

*Counsel for Proposed Amicus Curiae
Law Scholars*